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Introduction
Prostate cancer (PCa) is the second most common cancer in men worldwide and the sixth most common cause of death [1] . There is a large degree of variation worldwide in both incidence and mortality because of differences in genetic background, lifestyle, the availability of screening programmes, and treatments.
Men with germline mutations in breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) genes have an increased risk of PCa. The relative risk of PCa by 65 yr is estimated at 1.8-fold to 4.5-fold for BRCA1 carriers [2, 3] and at 2.5-fold to 8.6-fold for BRCA2 carriers [4] [5] [6] . A number of retrospective studies consistently report that BRCA2 carriers present at a younger age with aggressive disease, higher rates of lymph node involvement, distant metastasis at diagnosis, and a higher mortality rate compared with noncarriers [7] [8] [9] [10] [11] [12] . While there is debate about whether there is an increased risk of PCa for BRCA1 carriers, there is increasing evidence that these men also present with more aggressive disease [7, 9, 13] . In addition, BRCA2 mutation status has been confirmed as an independent prognostic factor for poorer outcome [7] . Therefore, targeted screening of BRCA1/2 carriers for earlier detection may be beneficial.
The prostate-specific antigen (PSA) test is the most effective PCa biomarker currently available; however, its limitations are well documented. Expert groups have concluded that data from existing clinical trials-notably the Prostate, Lung, Colorectal and Ovary screening study (PLCO) [14] and the European Randomised Study of Screening for Prostate Cancer (ERSPC) [15] -are insufficient to recommend routine general population PSA screening. The main scientific challenge is to differentiate between men who will benefit from screening and men who will not, reducing overdiagnosis and overtreatment while maintaining benefits (ie, lower mortality).
There is no international consensus on targeting screening at men at higher risk. There have been a limited number of studies of screening in men with a family history of PCa [16] [17] [18] . Most of the studies support the use of targeted screening; however, methodological differences make it difficult to draw conclusions from these data [16, 17, [19] [20] [21] [22] [23] [24] [25] [26] . The IMPACT study (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls; www.impact-study.co.uk) is an international, multicentre study evaluating the role of targeted PSA screening in men with BRCA1/2 mutations. The aims of IMPACT are to evaluate the utility of PSA screening, to determine PCa
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Materials and methods
The IMPACT study design and methods have previously been reported elsewhere [27, 28] and are summarised below (Fig. 1 ). The methods have been described previously [29, 30] . The results from the four kallikrein markers were combined to create a risk score (Rotterdam score) using a previously described model [30] .
Participants with PSA 3.0 ng/ml will undergo annual PSA screening for !5 yr, except participants in the Dutch cohort, who are screened biennially (because of the constraints of the ministerial approval).
Participants with PSA >3.0 ng/ml and a negative biopsy will undergo annual PSA testing, repeating the biopsy if PSA increases by >50%. All participants will be followed up for !5 yr to evaluate the cancer incidence and PCa-specific mortality and morbidity [27, 28] .
The local histopathologist at each centre reported the biopsy results to guide treatment in accordance with local guidelines. The Gleason score, clinical stage, and classification of disease into low, intermediate, or high risk of metastasis [31] were reported for each case. Central pathology review was performed by the study pathologist (C.S.F.) to ensure consistency and standardisation. Prostate core biopsies were assessed in accordance with International Society of Urological Pathology guidelines [32] (described previously [10, 33] ). Whenever high-grade prostate intraepithelial neoplasia (HG PIN) or atypical small acinar proliferation (ASAP) was detected, the biopsy was repeated within 3-6 mo. between evidence of PCa at biopsy and the Rotterdam score, and the Spearman correlation was used to determine the relationship between PSA measurements taken in the clinical and laboratory settings.
Statistical analysis
Results
Study population
A total of 2481 participants from 62 centres in 20 countries were recruited over 90 mo (Supplemental Table 1 ); there were 791 BRCA1 carriers and 531 BRCA1 controls, as well as 731 BRCA2 carriers and 428 BRCA2 controls) (Fig. 2) . The majority of participants were white (95%) and highly educated (measured using self-reported qualifications), and the mean age at enrolment was 54 yr (Table 1 ). Twenty-one percent of the men reported urinary symptoms, and 37% had previously had at least one PSA test. No statistically significant differences were observed among groups; 27% reported a family history of PCa in at least one blood relative.
3.2.
Prostate cancer detection rates at initial screening and positive predictive value of biopsy
Of the 2481 men, 199 (8.0%) had PSA >3.0 ng/ml (range: 3.0-27.0; median: 4.3) and were referred to a urologist to discuss prostate biopsy ( Fig. 2 ). Of these men, 162 (81.4%) underwent biopsy. Biopsies were declined because of concurrent health conditions (n = 7), the urologist's choosing to repeat the PSA test prior to biopsy resulting in a reading 3.0 ng/ml (n = 17), men changing their minds (n = 8), or reason missing (n = 5). Fifty-nine of 162 biopsies (36.4%) contained cancer. There was no significant difference in cancer detection rates between men who had or had not undergone PSA screening prior to study entry. No significant differences were seen with the Dutch cohort, in which men with prior PSA screening were excluded. Other than in the Dutch cohort, the prior screening levels were similar in all countries. The PCa detection rate was 2.4% (59 of 2481 men) ( Table 2 ). The detection rate for BRCA1 carriers was 2.3% (18 of 791); it was 1.9% (10 of 531) for BRCA1 controls, 3.3% (24 of 731) for BRCA2 carriers, and 1.6% (7 of 428) for BRCA2 controls, with no significant difference among groups. The number of cores taken at biopsy ranged from 6 to 20; however, there were no differences in the median or mean number of cores taken among groups ( Table 2 ). Four men had either ASAP or HG PIN (all mutation carriers) ( Central, and Southern Europe), and no statistically significant differences were observed. The PPV of biopsy using a PSA threshold of 3.0 ng/ml (ie, the number of cancers detected divided by the number of biopsies performed) was 36% (59 of 162) ( Table 2) . Broken down by genetic status, the PPV in BRCA1 carriers was 37.5% (18 of 48); in BRCA1 controls, 23.3% (10 of 43); in BRCA2 carriers, 48.0% (24 of 50); and in BRCA2 controls, 33.3% (7 of 21). There was no statistically significant difference among groups (Pearson chi-square test for BRCA1, p = 0.14; for BRCA2, p = 0.26).
There was no significant difference between either mean age at PCa diagnosis or PSA level among groups.
Twelve men (20%) reported urinary symptoms prior to diagnosis, and 20 men (34%) had a PSA test prior to study entry (29% BRCA2 carriers, 50% BRCA2 controls; 44% BRCA1 carriers, 33% BRCA1 controls). There was no difference observed in levels of PSA screening prior to study entry among groups.
Using the NICE classification [31, 34] , intermediate-or high-risk tumours were diagnosed in 11 of 18 BRCA1 carriers (61%) compared with 8 of 10 BRCA1 controls (80%) and in 17 of 24 BRCA2 carriers (71%) compared with 3 of 7 BRCA2 controls (43%) ( Table 3 ). There was no significant difference observed between genetic status and disease risk status. The PPV of biopsy using a PSA threshold of 3.0 ng/ml 
3.3.
Central analysis of prostate-specific antigen and the kallikrein panel
There was a strong correlation between PSA values measured in the clinical and laboratory settings (Spearman r = 0.85). Serum samples of 57 (24 with PCa) of the 162 men who underwent a biopsy were analysed for MSP and four kallikrein markers (Table 4) .
We found no association between PCa at biopsy and total PSA or MSP ( Table 5 ). We compared the proportion of PCa in mutation carriers with controls and found no association between PCa at biopsy and mutation status. There was an association of PCa at biopsy and Rotterdam score (Wald test p = 0.024). The discrimination of the Rotterdam model was 0.70 (95% confidence interval [CI], 0.56-0.84). For the outcome of high-grade cancer, the Rotterdam score was the only statistically significant predictor ( p = 0.009), with a discrimination of 0.86 (95% CI, 0.73-0.99). For 1202 of 2481 participants with available blood samples, we found a strong correlation of total PSA between measurements taken in the clinical and laboratory settings (Spearman r = 0.95).
Serious adverse events
Six study-related serious adverse events were reported, all occurring after biopsy. Complications occurred in 6 of 158 participants (3.8%), with five infections (3.2%) reported, two requiring hospitalisation. The sixth participant was hospitalised because of fainting after biopsy.
Discussion
In this paper we have presented the results of the first screening round of IMPACT, including the number and features of the PCa detected. With germline mutations in BRCA1 and BRCA2 being rare, the success of IMPACT has been in the formation of an international consortium of 62 centres with both clinical genetics and urologic collaboration. Enrolment was open until the required number of recruits was obtained in all four cohorts, exceeding the numbers required for statistical power in all groups. Compliance with the protocol was high, with 162 men with PSA >3.0 ng/ml (>81%) proceeding to biopsy. This number compares favourably with the 86% in the ERSPC [35] and the 31.5% in the PLCO study [35] [36] [37] . In the PLCO study, with no strict protocol to guide intervention, 74% of men with an abnormal screening test underwent further diagnostic evaluation, and 64% underwent biopsy within 3 yr [37] . Thus, a similar increase in compliance may be anticipated in IMPACT at subsequent screening rounds. The potential utility of multiparametric magnetic resonance imaging (MRI) as a screening tool before biopsy has been the subject of recent debate [38] ; however, the IMPACT protocol was designed prior to the use of MRI in this diagnostic capacity.
In total, 8% of the men had a positive PSA test (>3.0 ng/ml), which is lower than the 16.2% (range: 11.1-22.3% among sites) reported in the ERSPC general population screening study [35] . However, the ERSPC recruited an older cohort of men (55-75 yr), with a mean age of 61 yr compared with 54 yr in IMPACT. It is known that PSA increases with age, so higher PSA levels would be expected. In addition, a number of ERSPC centres used a threshold of 4.0 ng/ml rather than 3.0 ng/ml to determine biopsy, so the two studies are not entirely directly comparable. These results indicate that overbiopsy is not a concern in this younger cohort.
There is controversy about the PSA level used to trigger biopsy, with no clear consensus. The results presented show that while not statistically significant, the PPV of biopsy using a PSA threshold of 3.0 ng/ml is higher for BRCA2 carriers than for controls (48% vs 33%) and higher for BRCA1 carriers than controls (41% vs 23%). For BRCA2 carriers, this percentage is double the 24.1% reported in the ERSPC general population sample. This higher PPV observed in mutation carriers may be explained, at least in part, by the fact that the ERSPC screened older men. Also, given the younger age of the IMPACT cohort, the incidence of benign prostatic hypertrophy (BPH) may have been lower; the incidence of BPH increases with age, and BPH lowers the specificity of PSA screening [27, 39, 40] . These data suggest that lowering the PSA threshold for biopsy in BRCA2 carriers could potentially detect early-stage disease, thus reducing the need for more toxic treatments and ultimately reducing PCa mortality. However, this lowering would need to be balanced against the risk of potentially life-threatening side-effects of biopsy [41, 42] .
In IMPACT, men will be offered a prostate biopsy at the end of the study (at the centres with the capacity), which may provide evidence for the optimal PSA threshold for detecting clinically significant PCa in this cohort of higherrisk men.
The observed differences in PPV may also reflect the higher incidence and grade of PCa previously reported, particularly in BRCA2 carriers. The higher PPV in BRCA2 carriers suggests that PSA may have a higher specificity in this high-risk setting. However, as the number of cancers is relatively small, subsequent PSA screening rounds are essential to confirm this hypothesis. Evaluation of the panel of four kallikrein markers in subsequent screening rounds may provide further insights into the panel's potential role in predicting biopsy outcome [30] .
The ERSPC reported that 4.2% of men had a cancer diagnosis at the first screening round [43] . In IMPACT, the PCa detection rate was 2.4%, and two-thirds of the men in the cohort were previously unscreened. The younger age of the IMPACT sample is likely to explain this lower detection rate. More than two-thirds of the PCa detected in the BRCA2 carriers were classified as intermediate -or high -risk, supporting retrospective reports of a more aggressive phenotype and poorer prognosis in this group [7] [8] [9] [10] [11] [12] . Sixty-one percent of BRCA1 carriers were classified as having intermediate-or high-risk disease. By comparison, in the ERSPC, only 27.8% of the PCa diagnosed in the screened cohort were Gleason score !7 [35] . Longer-term follow-up will determine whether there is a difference in metastatic events and mortality between carriers and controls. From the PLCO study, after 13 yr of follow-up, there is no evidence to support the idea that organised PSA screening reduces mortality compared with opportunistic screening [14] . In contrast, after a median of 11 yr of followup, the ERSPC reported a 21% reduction in PCa-specific mortality in the screened cohort [15] . It is important to note that in the PLCO, 56% of men in the control arm had PSA screening, compared with 15% in the ERSPC.
The higher incidence of clinically significant disease in the BRCA2 mutation carriers, together with the significantly younger age of BRCA2 carriers with PSA >3.0 ng/ml, is an important observation in view of the younger age of this cohort compared with the ERSPC study. The only cancers detected in men <50 yr were in BRCA1 and BRCA2 carriers. These data add to the increasing evidence that BRCA1/2 carriers develop more aggressive disease, and at a younger age. Of note, the control groups also had a higher level of intermediate-or high-risk disease compared with the ERSPC. However, the number of cancers is relatively small, and with 19% of men declining biopsy, these data should be interpreted with caution.
The population incidence of PCa in each of the recruiting countries must be considered. The incidence in the majority of the countries is very similar, except in India and Malaysia [44] . Given the relatively low number of recruits from these regions, geographical variation is unlikely to have a major impact on the results. A limitation of IMPACT is that 95% of the men were white. Thus, the results cannot be generalised to all ethnic groups known to have a higher risk of PCa and a more aggressive phenotype (eg, black). A second limitation is that 37% of the cohort had previously had a PSA test. This fact could potentially bias the study to either having men with a lower PSA or having men with higher PSAs due to noncancerous causes. However, no difference in screening levels was observed among those men with and without cancer. A further limitation is that the control group was recruited from families known to have BRCA mutations. It is possible that this group of men has a different PCa risk profile than the general population.
Conclusions
The first screening round of IMPACT demonstrates that targeted screening for PCa in men with a genetic predisposition detects clinically significant disease. Using a PSA threshold of 3 ng/ml results in a low biopsy rate (8.0%) and a high PPV, particularly in BRCA2 carriers, for the detection of intermediate-and high-risk disease. Although the observed differences in PCa detection rates between carriers and controls was not statistically significant, the trend is clear. With larger numbers of PCa in the follow-up phase (5 yr), these differences, if sustained, are likely to be significant. Future screening rounds will determine the optimal frequency of PSA testing, determine the utility of PSA screening in BRCA1 carriers, and provide further data on the value of annual screening in BRCA2 carriers.
A previously published statistical model based on four kallikrein markers was able to predict biopsy outcome in participants with PSA >3 ng/ml with a discrimination of 0.86 for high-grade disease. Longer-term follow-up will be used to validate the role of the kallikrein panel in this population.
IMPACT is the first prospective study to demonstrate the use of germline genetic markers to identify men at higher risk of PCa, which has the potential to enable better risk stratification to inform targeted screening. These early results indicate that the tumours detected are more likely to need treatment based on national guidelines for management of more aggressive PCa. Therefore, our preliminary results support the use of PSA screening for BRCA2 carriers. 
